{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-005038","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.693703+00:00","generated_at":"2026-05-16T09:40:17.851219+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura receives $300K loans from controlling shareholder; warns of potential shutdown if no funding by Jan 2026","bullets":["On Dec 31, Jan 2, and Jan 16, 2026, Acura received $100K each from Abuse Deterrent Pharma (65% owner), bringing note principal to $9.59M.","Note bears 5.25% interest; default rate 7.5%; events of default include bankruptcy and failure to pay within 5 days.","Company states that without additional financing by end of January 2026, it will scale back operations or seek bankruptcy protection.","AD Pharma holds ~65% of Acura's common stock; entity controlled by Mr. Schutte, who directly owns ~13%.","Proceeds fund day-to-day operations; company warns of potential complete loss of shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-005038","json":"https://secwatch.observer/filing/0001104659-26-005038.json","markdown":"https://secwatch.observer/filing/0001104659-26-005038.md","text":"https://secwatch.observer/filing/0001104659-26-005038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/0001104659-26-005038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/tm263622d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:40:17.851219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88a0a2d88135956b8f94c8f0df07beb78bf09438","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of December 31, 2025, January 2, 2026 and January 16, 2026 we received loans of $100,000 from Abuse Deterrent Pharma, LLC (\"AD Pharma\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/0001104659-26-005038-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$100,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}